Suboptimal hemoglobin levels: do they impact patients and their therapy? Audience responses.
Ludwig
H
H
First Department of Medicine and Medical Oncology, Wilhelminenspital, Vienna, Austria.
Pecorelli
S
S
D000368:Aged; D000740:Anemia / Q000139:chemically induced* / Q000523:psychology / Q000628:therapy; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001803:Blood Transfusion; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000627:therapeutic use; D005060:Europe; D019317:Evidence-Based Medicine; D005260:Female; D006397:Hematinics / Q000627:therapeutic use; D006454:Hemoglobins / Q000187:drug effects / Q000378:metabolism*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy*; D010818:Practice Patterns, Physicians'; D011788:Quality of Life; D011994:Recombinant Proteins; D016896:Treatment Outcome; D014481:United States
D000970:Antineoplastic Agents; D006397:Hematinics; D006454:Hemoglobins; D011994:Recombinant Proteins; D004921:Erythropoietin; D000068817:Epoetin Alfa